Insider transactions

James A Geraghty

CIK 1239746 · Senior Vice President · last filed 2026-07-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$907.1K
Companies
8
Total Filings
100
Lifetime Open-Market Net
-$484.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

GENZ price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O IDERA PHARMACEUTICALS, INC.
167 SIDNEY STREET
CAMBRIDGE, MA 02139
Related Filers
COLUMBIA LABORATORIES INC — 14 joint filings, latest 2018-08-15
PALVELLA THERAPEUTICS, INC. — 14 joint filings, latest 2024-12-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FULC Director 90,714 $3.77 $342.0K $91.6K 9 2026-07-02
VYGR Director 76,588 $2.45 $187.6K $113.1K 13 2026-06-11
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director 0 $13.60 $0 $105.7K 13 2024-12-12
Orchard Therapeutics plc (ORTX) Delisted Director 0 $16.70 $0 $0 5 2024-01-24
Aceragen, Inc. (IDRA) Delisted Director 7,032 $7.22 $50.8K $817.0K 25 2022-06-27
JUNIPER PHARMACEUTICALS INC (JNP) Delisted Director 0 — — $455.0K 13 2018-08-15
GENZ Senior Vice President 9,845 $38.34 $377.5K -$2.08M 7 2011-04-06
GTC BIOTHERAPEUTICS INC (GTCB) Delisted Director 19,163 — — $8.7K 15 2010-01-05

Recent Filings · Page 4 of 10

100 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-15 FULC Grant (A) — $0 EDGAR
2020-06-05 VYGR Grant (A) — $0 EDGAR
2020-05-19 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2020-04-03 Aceragen, Inc. (IDRA) Delisted Grant (A) +14,926 $19.1K EDGAR
2020-01-28 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2019-07-18 FULC Grant (A) — $0 EDGAR
2019-06-17 VYGR Grant (A) — $0 EDGAR
2019-06-06 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2019-01-29 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2018-09-12 VYGR Buy (P) +3,000 $58.2K EDGAR
Showing 31–40 of 100
Page 4 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.